Susquehanna International Group’s Century Therapeutics IPSC Stock Holding History

Susquehanna International Group’s Portfolio IPSC Stock Details IPSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$512K	Buy	226,687 +176,583	+352%	+$371K	﹤0.01%	9599
2025 Q4	$49.8K	Sell	50,104 -17,820	-26%	-$10.9K	﹤0.01%	11750
2025 Q3	$33.8K	Sell	67,924 -132,027	-66%	-$71.2K	﹤0.01%	11955
2025 Q2	$112K	Buy	199,951 +142,516	+248%	+$76.5K	﹤0.01%	11721
2025 Q1	$27.3K	Buy	57,435 +24,040	+72%	+$18.1K	﹤0.01%	12038
2024 Q4	$33.7K	Buy	+33,395	New	+$45.5K	﹤0.01%	11813
2024 Q1	–	Sell	-22,629	Closed	-$75.1K	–	12720
2023 Q4	$75.1K	Buy	+22,629	New	+$41.2K	﹤0.01%	11516
2023 Q2	–	Sell	-10,747	Closed	-$37.3K	–	12596
2023 Q1	$37.3K	Buy	+10,747	New	+$47.2K	﹤0.01%	11826
2022 Q3	–	Sell	-14,152	Closed	-$149K	–	13643
2022 Q2	$119K	Buy	+14,152	New	+$139K	﹤0.01%	11289
2021 Q3	–	Sell	-23,001	Closed	-$675K	–	13137
2021 Q2	$675K	Buy	+23,001	New	+$584K	﹤0.01%	8834

Other funds holding IPSC

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Susquehanna International Group's IPSC Position: Q1 2026 in Review

Susquehanna International Group increased its Century Therapeutics (IPSC) stake by 352% in Q1 2026, buying an estimated $371K and bringing the position to 226,687 shares worth $512K. The position accounts for ﹤0.01% of the portfolio, ranked #9599.

Susquehanna International Group first reported a position in IPSC in Q2 2021 and has held it in 10 quarters since. The position peaked at $675K in Q2 2021. 72 funds tracked by Wall St. Rank hold IPSC as of Q1 2026.

Susquehanna International Group held 226,687 shares of Century Therapeutics worth $512K as of Q1 2026.
Susquehanna International Group bought 176,583 Century Therapeutics shares in Q1 2026, an estimated $371K.
Century Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #9599 holding.
Susquehanna International Group first reported a position in Century Therapeutics in Q2 2021 and has held it in 10 quarters since.
Susquehanna International Group's Century Therapeutics position peaked at $675K in Q2 2021.
72 funds tracked by Wall St. Rank held Century Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.